Targeting β-cell mass in type 2 diabetes:: Promise and limitations of new drugs based on incretins

被引：89

作者：

Salehi, Marzieh ^{[1
]}

Aulinger, Benedikt A. ^{[1
]}

D'Alessio, David A. ^{[1
]}

机构：

[1] Univ Cincinnati, Dept Med, Div Endocrinol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA

来源：

ENDOCRINE REVIEWS | 2008年 / 29卷 / 03期

关键词：

D O I：

10.1210/er.2007-0031

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic beta-cells or a reduction in beta-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on beta-cell physiology as well as by expanding or at least maintaining beta-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

引用

页码：367 / 379

页数：13

共 163 条

[1] Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells [J].

Abraham, EJ ;

Leech, CA ;

Lin, JC ;

Zulewski, H ;

Habener, JF .

ENDOCRINOLOGY, 2002, 143 (08) :3152-3161

[2] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men [J].

Agerso, H ;

Jensen, LB ;

Elbrond, B ;

Rolan, P ;

Zdravkovic, M .

DIABETOLOGIA, 2002, 45 (02) :195-202

[3] Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus [J].

Ahren, B ;

Larsson, H ;

Holst, JJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :473-478

[4] Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes [J].

Ahrén, B ;

Gomis, R ;

Standl, E ;

Mills, D ;

Schweizer, A .

DIABETES CARE, 2004, 27 (12) :2874-2880

[5] FUNCTIONAL GIP RECEPTORS IN A HAMSTER PANCREATIC BETA-CELL LINE, IN 111 - SPECIFIC BINDING AND BIOLOGICAL EFFECTS [J].

AMIRANOFF, B ;

VAUCLINJACQUES, N ;

LABURTHE, M .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 123 (02) :671-676

[6] Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].

Amori, Renee E. ;

Lau, Joseph ;

Pittas, Anastassios G. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206

[7] Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J].

Aschner, Pablo ;

Kipnes, Mark S. ;

Lunceford, Jared K. ;

Sanchez, Matilde ;

Mickel, Carolyn ;

Williams-Herman, Debora E. .

DIABETES CARE, 2006, 29 (12) :2632-2637

[8] Diabetes mellitus and genetically programmed defects in β-cell function [J].

Bell, GI ;

Polonsky, KS .

NATURE, 2001, 414 (6865) :788-791

[9] PHYSIOLOGIC EVALUATION OF FACTORS CONTROLLING GLUCOSE-TOLERANCE IN MAN - MEASUREMENT OF INSULIN SENSITIVITY AND BETA-CELL GLUCOSE SENSITIVITY FROM THE RESPONSE TO INTRAVENOUS GLUCOSE [J].

BERGMAN, RN ;

PHILLIPS, LS ;

COBELLI, C .

JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (06) :1456-1467

[10] Osteoblast-derived cells express functional glucose dependent insulinotropic peptide receptors [J].

Bollag, RJ ;

Zhong, Q ;

Phillips, P ;

Min, L ;

Zhong, L ;

Cameron, R ;

Mulloy, AL ;

Rasmussen, H ;

Qin, F ;

Ding, KH ;

Isales, CM .

ENDOCRINOLOGY, 2000, 141 (03) :1228-1235

← 1 2 3 4 5 6 7 8 9 10 →